Dare Bioscience, Inc. (DARE)
DARE Stock Price Chart
Explore Dare Bioscience, Inc. interactive price chart. Choose custom timeframes to analyze DARE price movements and trends.
DARE Company Profile
Discover essential business fundamentals and corporate details for Dare Bioscience, Inc. (DARE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Apr 2014
Employees
23.00
Website
https://darebioscience.comCEO
Sabrina Martucci Johnson
Description
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
DARE Financial Timeline
Browse a chronological timeline of Dare Bioscience, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.33, while revenue estimate is $1.67k.
Earnings released on 14 May 2026
EPS came in at -$0.20 surpassing the estimated -$0.33 by +39.39%, while revenue for the quarter reached $152.46k , beating expectations by +464.65%.
Earnings released on 26 Mar 2026
EPS came in at -$0.02 surpassing the estimated -$0.24 by +91.67%, while revenue for the quarter reached $1.02m , beating expectations by +36.22%.
Earnings released on 13 Nov 2025
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $2.26k , missing expectations by -99.70%.
Earnings released on 14 Aug 2025
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached -$21.17k , missing expectations by -114.38%.
Earnings released on 13 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.63 by +20.63%, while revenue for the quarter reached $25.43k , missing expectations by -95.76%.
Earnings released on 31 Mar 2025
EPS came in at -$0.64 surpassing the estimated -$0.66 by +3.03%, while revenue for the quarter reached -$63.65k , missing expectations by -106.36%.
Earnings released on 14 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.60 by +8.33%, while revenue for the quarter reached $41.69k , missing expectations by -95.83%.
Earnings released on 12 Aug 2024
EPS came in at $1.52 surpassing the estimated -$0.57 by +366.67%, while revenue for the quarter reached $22.44k , missing expectations by -99.62%.
Stock split effective on 1 Jul 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$0.84 falling short of the estimated -$0.72 by -16.67%, while revenue for the quarter reached $9.30k , missing expectations by -96.42%.
Earnings released on 28 Mar 2024
EPS came in at -$0.72 surpassing the estimated -$1.08 by +33.33%, while revenue for the quarter reached $1.81m , missing expectations by -23.92%.
Earnings released on 9 Nov 2023
EPS came in at -$1.08 surpassing the estimated -$1.20 by +10.00%, while revenue for the quarter reached $1.00m , missing expectations by -20.63%.
Earnings released on 10 Aug 2023
EPS came in at -$1.20 matching the estimated -$1.20.
Earnings released on 11 May 2023
EPS came in at -$1.08 surpassing the estimated -$1.20 by +10.00%.
Earnings released on 30 Mar 2023
EPS came in at -$2.28 falling short of the estimated -$1.80 by -26.67%, while revenue for the quarter reached $10.00bn , beating expectations by +502.41k%.
Earnings released on 10 Nov 2022
EPS came in at -$0.96 surpassing the estimated -$1.32 by +27.27%.
Earnings released on 9 Aug 2022
EPS came in at $0.06 surpassing the estimated -$0.06 by +196.98%, while revenue for the quarter reached $10.00m , meeting expectations.
Earnings released on 12 May 2022
EPS came in at -$1.20 surpassing the estimated -$1.68 by +28.57%.
Earnings released on 31 Mar 2022
EPS came in at -$2.16 surpassing the estimated -$2.52 by +14.29%.
Earnings released on 10 Nov 2021
EPS came in at -$2.16 falling short of the estimated -$1.32 by -63.64%.
Earnings released on 12 Aug 2021
EPS came in at -$2.16 falling short of the estimated -$1.80 by -20.00%.
DARE Stock Performance
Access detailed DARE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
